Publikation
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.
Wissenschaftlicher Artikel/Review - 09.01.2024
Rastogi Priya, O'Shaughnessy Joyce, Martín Miguel, Boyle Frances, Cortes Javier, Rugo Hope S, Goetz Matthew P, Hamilton Erika, Huang Chiun-Sheng, Senkus Elzbieta, Tryakin Alexey, Cicin Irfan, Testa Laura, Neven Patrick, Huober Jens, Shao Zhimin, Wei Ran, Andre Valerie A M, Munoz Maria, San Antonio Belen, Shahir Ashwin, Harbeck Nadia, Johnston Stephen R D
Rastogi, Priya
7
0
O'Shaughnessy, Joyce
7
0
Martín, Miguel
8
0
Boyle, Frances
2
0
Cortes, Javier
3
0
Rugo, Hope S
8
0
Goetz, Matthew P
6
0
Hamilton, Erika
3
0
Huang, Chiun-Sheng
2
0
Senkus, Elzbieta
1
0
Tryakin, Alexey
Cicin, Irfan
3
0
Testa, Laura
1
0
Neven, Patrick
21
0
Huober, Jens
Chefarzt/ChefärztinBrustzentrum St.Gallen, Medizinische Onkologie und Hämatologie · Dept. IV, Dept. I
298
12
Shao, Zhimin
Wei, Ran
3
0
Andre, Valerie A M
4
0
Munoz, Maria
1
0
San Antonio, Belen
2
0